Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095516 | PMC |
| http://dx.doi.org/10.1007/s40273-022-01144-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Drug-related exanthema under immunotherapy and targeted oncological therapy].
Dermatologie (Heidelb)
June 2024
Klinik für Dermatologie, Allergologie und Venerologie, Universitätsmedizin Essen, Hufelandstr. 55, 45122, Essen, Deutschland.
Background: Oncological therapies can cause a variety of mucocutaneous adverse events. Exanthematous adverse events can be challenging in the context of the urgent need for cancer treatment due to their spread, sometimes rapid progression, and mucous membrane or organ involvement.
Materials And Methods: This article provides an overview of the most important exanthematic dermatoses as side effects of modern drug-based tumor therapies with diagnostic and therapeutic information for clinicians, taking into account the current literature and guidelines.
Correction to: Mogamulizumab for Previously Treated Mycosis Fungoides and Sézary Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Pharmacoeconomics
May 2022
Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+ (MUMC+), P. Debyelaan 25, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.
Cutaneous T-cell lymphomas-An update 2021.
Hematol Oncol
June 2021
Department of Dermatology, Venereology and Allergology, University Medical Center Göttingen, Göttingen, Germany.
Cutaneous T-cell lymphomas (CTCL) represent the majority of primary cutaneous lymphomas (CL). Mycosis fungoides (MF) and cutaneous CD30+ lymphoproliferative disorders account for 80% of all CTCL. CTCL show overlapping histological features.
View Article and Find Full Text PDFClinical factors to predict outcome following mogamulizumab in adult T-cell leukemia-lymphoma.
Int J Hematol
November 2018
Atomic Bomb Disease and Hibakusha Medicine Unit, Department of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
Adult T-cell leukemia-lymphoma (ATL) is a distinct T-cell malignancy caused by human T-cell leukemia virus type-1; the prognosis is very poor. Mogamulizumab (Moga), an antibody drug for CC chemokine receptor type 4, has been introduced for the treatment of ATL. However, the prognosis of relapsed or refractory ATL remains poor and the characteristics of patients who derive clinical benefit from treatment with Moga remain poorly understood.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!